GRP receptor-mediated immediate early gene expression and transcription factor Elk-1 activation in prostate cancer cells

Bombesin (BN) and its mammalian homologue gastrin-releasing peptide (GRP) have been shown to play an important role in human cancer as autocrine and paracrine growth factors. Prostatic neuroendocrine cells are thought to secrete these regulatory peptides and they may therefore interact with their specific, aberrantly expressed GRP receptor (GRP-R) in prostate cancer. In this study, we investigated the effect of BN on immediate early gene expression in two androgen-independent prostate cancer cell lines DU-145 and PC-3 with functional GRP receptor. We found that BN induced c-fos mRNA expression in both cell lines in a time-dependent manner. In contrast, c-jun mRNA was only modestly induced in DU-145 cells but not at all in PC-3 cells. On the protein level, we detected BN-induced stimulation of the c-fos gene product but not of c-jun protein. Sustained increase of the c-myc gene product was detectable in PC-3 but not in DU-145 cells. Concurrently, we demonstrated BN-dependent activation of the transcription factor Elk-1 and significant increase of cell proliferation in both prostate cancer cell lines. Taken together, these data suggest that BN acts as a mitogen in prostate cancer and this might be associated with the activation of the transcription factor Elk-1 and the immediate early gene c-fos.

[1]  E. Rozengurt.  Signal transduction pathways in the mitogenic response to G protein–coupled neuropeptide receptor agonists , 1998, Journal of cellular physiology.

[2]  P. Comoglio,et al.  Bombesin stimulation of c-fos and c-myc gene expression in cultures of Swiss 3T3 cells. , 1986, Experimental cell research.

[3]  E. Rozengurt,et al.  Early signals underlying the induction of the c-fos and c-myc genes in quiescent fibroblasts: studies with bombesin and other growth factors. , 1988, Progress in nucleic acid research and molecular biology.

[4]  P. A. Sant'agnese,et al.  Neuroendocrine cells of the prostate and neuroendocrine differentiation in prostatic carcinoma: a review of morphologic aspects , 1998 .

[5]  C. Logothetis,et al.  Differential effects of peptide hormones bombesin, vasoactive intestinal polypeptide and somatostatin analog RC-160 on the invasive capacity of human prostatic carcinoma cells. , 1993, The Journal of urology.

[6]  P. Abrahamsson.  Neuroendocrine differentiation and hormone‐refractory prostate cancer , 1996, The Prostate. Supplement.

[7]  S. Chevalier,et al.  Bombesin specifically induces intracellular calcium mobilization via gastrin-releasing peptide receptors in human prostate cancer cells. , 1996, Journal of molecular endocrinology.

[8]  J. Gutkind.  Regulation of Mitogen-Activated Protein Kinase Signaling Networks by G Protein-Coupled Receptors , 2000, Science's STKE.

[9]  P. di Sant'Agnese,et al.  Neuroendocrine differentiation in prostatic malignancy , 1996, Cancer.

[10]  T. Moody,et al.  Bombesin activates MAP kinase in non-small cell lung cancer cells , 1999, Peptides.

[11]  T. Moody,et al.  Bombesin stimulates c-fos and c-jun mRNAs in small cell lung cancer cells , 1995, Peptides.

[12]  R. T. Jensen,et al.  Mammalian bombesin receptors , 1995, Medicinal research reviews.

[13]  T. Gress,et al.  GRP-receptor-mediated signal transduction, gene expression and DNA synthesis in the human pancreatic adenocarcinoma cell line HPAF , 2001, Peptides.

[14]  J. Battey,et al.  Bombesin stimulates the in vitro growth of a human gastric cancer cell line , 1994, Journal of cellular physiology.

[15]  J C Reubi,et al.  Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. , 1999, Cancer research.

[16]  H. Mehmet,et al.  Multiple synergistic signal transduction pathways regulate c-fos expression in Swiss 3T3 cells: the role of cyclic AMP. , 1990, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[17]  P. Abrahamsson.  Neuroendocrine cells in tumour growth of the prostate. , 1999, Endocrine-related cancer.

[18]  John D. Minna,et al.  Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer , 1985, Nature.

[19]  P. Troncoso,et al.  In situ hybridization for gastrin‐releasing peptide receptor (GRP receptor) expression in prostatic carcinoma , 1998, International journal of cancer.

[20]  A. Schally,et al.  Characterization of high‐affinity receptors for bombesin/gastrin releasing peptide on the human prostate cancer cell lines PC‐3 and DU‐145: Internalization of receptor bound 125I‐(Tyr4) bombesin by tumor cells , 1994, The Prostate.

[21]  E. Rozengurt,et al.  Bombesin stimulation of fibroblast mitogenesis: specific receptors, signal transduction and early events. , 1990, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[22]  P. Abrahamsson.  Neuroendocrine differentiation in prostatic carcinoma , 1999, The Prostate.

[23]  Structure-function studies of ETS transcription factors. , 2000, Critical reviews in oncogenesis.

[24]  L. Bégin,et al.  Neuroendocrine differentiation and the bombesin/gastrin‐releasing peptide family of neuropeptides in the progression of human prostate cancer , 1998, The Prostate. Supplement.

[25]  A. Schally,et al.  Potentiation of the inhibitory effect of growth hormone‐releasing hormone antagonists on PC‐3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways , 2000, The Prostate.

[26]  S. Chevalier,et al.  Bombesin stimulates the motility of human prostate‐carcinoma cells through tyrosine phosphorylation of focal adhesion kinase and of integrin‐associated proteins , 1997, International journal of cancer.

[27]  V. Sementchenko,et al.  Ets target genes: past, present and future , 2000, Oncogene.

[28]  M. Ciomei,et al.  Bombesin stimulates growth of human prostatic cancer cells in vitro , 1990, Cancer.

[29]  A. Schally,et al.  Somatostatin analog RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of androgen-independent DU-145 human prostate cancer line in nude mice. , 1993, Cancer letters.

[30]  R. Bravo,et al.  Bombesin induces c-fos and c-myc expression in quiescent Swiss 3T3 cells. Comparative study with other mitogens. , 1987, Experimental cell research.

[31]  A. Sharrocks.  The ETS-domain transcription factor family , 2001, Nature Reviews Molecular Cell Biology.

[32]  E. Rozengurt,et al.  Bombesin induction of c‐fos and c‐myc proto‐oncogenes in Swiss 3T3 cells: Significance for the mitogenic response , 1987, Journal of cellular physiology.

[33]  P. Schellhammer,et al.  Calcium signaling in prostate cancer cells: Evidence for multiple receptors and enhanced sensitivity to bombesin/GRP , 1997, The Prostate.

[34]  A. Schally,et al.  Presence of receptors for bombesin/gastrin‐releasing peptide and mRNA for three receptor subtypes in human prostate cancers , 2000, The Prostate.

[35]  K. Szepesházi,et al.  Inhibition of growth of OV-1063 human epithelial ovarian cancers and c- jun and c- fos oncogene expression by bombesin antagonists , 2000, British Journal of Cancer.

[36]  E. Rozengurt.  Bombesin stimulation of mitogenesis. Specific receptors, signal transduction, and early events. , 1990, The American review of respiratory disease.

[37]  R. Jensen,et al.  A bombesin receptor subtype-3 peptide increases nuclear oncogene expression in a MEK-1 dependent manner in human lung cancer cells. , 2001, European journal of pharmacology.

[38]  A. Schally,et al.  Luteinizing hormone‐releasing hormone antagonist Cetrorelix (SB‐75) and bombesin antagonist RC‐3940‐II inhibit the growth of androgen‐independent PC‐3 prostate cancer in nude mice , 1997, The Prostate.

[39]  J. Vilches,et al.  In vitro characterization of bombesin and calcitonin on the proliferation of PC3, DU 145 and LNCaP cancer prostatic cell lines. , 1996, The International journal of developmental biology.

[40]  A. Schally,et al.  Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II. , 1997, European journal of cancer.

[41]  J. Swantek,et al.  New insights into the control of MAP kinase pathways. , 1999, Experimental Cell Research.

[42]  D. Xiao,et al.  The human gastrin-releasing peptide receptor gene structure, its tissue expression and promoter. , 2001, Gene.

[43]  J. Millar,et al.  Bombesin stimulation of c-fos expression and mitogenesis in Swiss 3T3 cells: the role of prostaglandin E2-mediated cyclic AMP accumulation. , 1990, Experimental cell research.

[44]  R. Muise-Helmericks,et al.  Signal transduction and the Ets family of transcription factors , 2000, Oncogene.

[45]  A. Schally,et al.  in vivo inhibition of PC‐3 human androgen‐independent prostate cancer by a targeted cytotoxic bombesin analogue, AN‐215 , 2000, International journal of cancer.

[46]  P. A. Sant'agnese,et al.  Neuroendocrine differentiation in prostatic carcinoma: An update , 1998 .